The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 2 of the 18 sources its claims cite were checked for support.
Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
Open accessPublished version of a preprint
Abstract
A key public health need is to identify individuals at high risk for a given disease to enable enhanced screening or preventive therapies. Because most common diseases have a genetic component, one important approach is to stratify individuals based on inherited DNA variation1. Proposed clinical applications have largely focused on finding carriers of rare monogenic mutations at several-fold increased risk. Although most disease risk is polygenic in nature2–5, it has not yet been possible to use polygenic predictors to identify individuals at risk comparable to monogenic mutations. Here, we develop and validate genome-wide polygenic scores for five common diseases. The approach identifies 8.0, 6.1, 3.5, 3.2, and 1.5% of the population at greater than threefold increased risk for coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, and breast cancer, respectively. For coronary artery disease, this prevalence is 20-fold higher than the carrier frequency of rare monogenic mutations conferring comparable risk6. We propose that it is time to contemplate the inclusion of polygenic risk prediction in clinical care, and discuss relevant issues. Genome-wide polygenic risk scores derived from GWAS data for five common diseases can identify subgroups of the population with risk approaching or exceeding that of a monogenic mutation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
25 Own result · 9 Not checked yet · 7 Own method · 3 Own interpretation · 2 No basis given · 1 Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“GPSCAD performed substantially better than two previously published polygenic scores for coronary artery disease that included 50 and 49,310 variants, respectively (Supplementary Table 7 and Supplementary Fig. 1).17,18”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Supportedcites [17] Tada, H. et al. Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history. Eur. Heart J. 37, 561–567 (2016). source
The Methods (Modelling of genetic risk score) identify this paper’s GRS50 as a 50-SNP score for coronary heart disease, supporting its citation as the previously published 50-variant score. The comparison with GPSCAD is presented as the citing paper’s own analysis, not as a result attributed to this source. (LLM, conf=0.91)
- Supportedcites [18] Abraham, G. et al. Genomic prediction of coronary heart disease. Eur. Heart J. 37, 3267–3278 (2016). source
The citation identifies the previously published 49,310-variant score used as a comparator. Abraham et al. report generating that score in Abstract > Methods and results; the GPSCAD performance comparison is the citing authors’ own result, attributed to their supplementary table and figure. (LLM, conf=0.91)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, even for our middle-aged study population, practicing clinicians could not identify the 8% of individuals at ≥3-fold risk based on GPSCAD in the absence of genotype information (Supplementary Table 8).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.5% of the population at ≥3-fold risk and the top 1% had 3.30-fold risk. (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 6.1% of the population at ≥3-fold risk and the top 1% had 4.63-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, 0.1% of women had ≥5-fold risk of breast cancer—corresponding to a breast cancer prevalence of 19.0% in this group versus 4.2% in the remaining 99.9% of the distribution.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The polygenic predictor identified 3.2% of the population at ≥3-fold risk and the top 1% had 3.87-fold risk (Tables 2 & 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This predictor performed equivalently well in the testing dataset, with AUC of 0.81.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plainn = 288,978- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results for CAD generalized to four other diseases: risk increased sharply in the right tail of the GPS distribution (Figure 3).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In our testing dataset, 19.8% of participants were at ≥3-fold increased risk for at least one of the five diseases studied (Table 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 8
- Probably not a substantial claim. 6
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The predictors had AUC ranging from 0.79 – 0.81 in the validation set, with the best predictor (GPSCAD) involving 6,630,150 variants (Supplementary Table 1).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelationaln = 120,280- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Across the population, GPSCAD is normally distributed with the empirical risk of CAD rising sharply in the right tail of the distribution, from 0.8% in the lowest percentile to 11.1% in the highest percentile (Figure 2).”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“In order to analyze individuals with a relatively homogenous ancestry and owing to small percentages of non-British individuals, the present analysis was restricted to the white British ancestry individuals.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Whereas identifying carriers of rare monogenic mutations requires sequencing of specific genes and careful interpretation of the functional effects of mutations found, polygenic scores can be readily calculated for many diseases simultaneously, based on data from a single genotyping array.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
plainn = 2- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Our validation and testing was performed in the UK Biobank population.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“These initial efforts were hampered by three challenges: (i) the small size of initial genome-wide association studies (GWAS), which affected the precision of the estimated impact of individual variants on disease risk; (ii) limited computational methods for creating GPS; and (iii) lack of large datasets needed to validate and test GPS.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results above show that, for a number of common diseases, polygenic risk scores can now identify a substantially larger fraction of the population than found by rare monogenic mutations, at comparable or greater disease risk.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The vast majority of common disease occurs in individuals without rare monogenic mutations.
In the paper
“Individuals who volunteered for the UK Biobank tended to be more healthy than the general population;27”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [27] Fry, A. et al. Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population. Am. J. Epidemiol. 186, 1026–1034 (2017). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In both cases, it is important to recognize that the risk associated with a high polygenic score may not reflect a single underlying mechanism, but rather the combined influence of multiple pathways.28”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [28] Khera, A. V. & Kathiresan, S. Is coronary atherosclerosis one disease or many? Setting realistic expectations for precision medicine. Circulation 135, 1005–1007 (2017). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, we previously showed that a high polygenic risk for CAD may be offset by either of two interventions: adherence to a healthy lifestyle or cholesterol-lowering therapy with statin medications.19–21”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [19] Khera, A. V. et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. N. Engl. J. Med. 375, 2349–2358 (2016). source
- Not checked yetcites [20] Mega, J. L. et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 385, 2264–2271 (2015). source
- Not checked yetcites [21] Natarajan, P. et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation 135, 2091–2101 (2017). source
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“UK Biobank samples were not included in any of the five discovery GWAS studies.”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Polygenic score derivation
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“An important example is the presence of a familial hypercholesterolemia mutation in 0.4% of the population, which confers an up to 3-fold increased risk for coronary artery disease (CAD).6”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [6] Abul-Husn, N. S. et al. Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science 354, pii: aaf7000 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Another example is the p.E508K missense mutation in HNF1A, with carrier frequency of 0.1% of the general population and 0.7% of Latinos,8 which confers up to 5-fold increased risk for type 2 diabetes.9”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Abstract
What the sources say
- Not checked yetcites [8] Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536, 285–291 (2016). source
- Not checked yetcites [9] Estrada, K. et al. Association of a low-frequency variant in HNF1A with type 2 diabetes in a Latino population. JAMA 311, 2305–2314 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The vast majority of common disease occurs in individuals without rare monogenic mutations.
“Although ascertainment of monogenic mutations can be highly relevant for carriers and their families, the vast majority of disease occurs in those without such mutations.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, integrated models of PRS together with other lifestyle and clinical factors have enabled clinicians to more accurately quantify the risk of heart attack for patients;”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This enthusiasm is driven by observations that a polygenic burden of LDL-increasing SNPs can confer monogenic-equivalent risk of cardiovascular disease, with polygenic scores improving clinical models for risk assessment and statin prescription that can reduce coronary heart disease and improve healthcare delivery efficiency5–7.”
From Clinical use of current polygenic risk scores may exacerbate health disparities (2019) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Using polygenic scores, it is now possible to combine information from millions of genomic variants to identify people whose overall polygenic risk of coronary artery disease is as high as that of patients with monogenic lipid disorders such as familial hypercholesterolemia [23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, they have contributed new approaches to risk prediction for adverse phenotypes related to heart disease [21–23].”
From Interpreting polygenic scores, polygenic adaptation, and human phenotypic differences (2019) · cites this paper as [23]
In the citing paper
“As described below, findings from GWAS have increasing translational impact through identification of novel therapeutic targets67, prioritization (and deprioritization) of existing ones68 and development of polygenic scores that quantify individual genetic risk69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“The development of robust polygenic scores for several common diseases has been catalysed by more precise per-variant effect estimates from larger GWAS datasets, improved algorithms for combining information across millions of single-nucleotide polymorphisms, and large-scale biobanks that support score validation69,146,147.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“For example, a genome-wide polygenic score for heart attack, incorporating 6.6 million variants, indicates that 5% of European-descent individuals have a risk of future cardiac events equivalent to that seen in those with less frequent monogenic forms of hypercholesterolaemia69.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
In the citing paper
“This paper used large-scale genetic data to demonstrate the clinical potential of the polygenic scores that can be constructed for many common diseases, emphasizing that, in some situations, the lifetime risk of disease for those with the highest scores approaches that of established monogenic disease.”
From A brief history of human disease genetics (2020) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Statistical analysis within the testing dataset
“For each disease, the GPS with the best discriminative capacity in the testing dataset was calculated in the testing dataset of 288,278 participants”
§ Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations > Online Methods: > Testing cohort
“The testing dataset was comprised of 288,978 UK Biobank Phase 2 participants distinct from those in the validation dataset described above.”
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
A global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Self-citationVos, T., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., Abdulkader, R. S., Abdulle, A. M., Abebo, T. A., Abera, S. F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32154-2 · Cited by 13,220
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Second-generation PLINK: rising to the challenge of larger and richer datasets
Chang, C. C., Chow, C. C., Tellier, L. C., Vattikuti, S., Purcell, S. M., & Lee, J. J. (2015) · Gigascience · doi:10.1186/s13742-015-0047-8 · Cited by 12,709
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Self-citationVos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
January, C. T., Wann, L. S., Alpert, J. S., Calkins, H. G., Cigarroa, J. E., Cleveland, J. C., CONTI, J. B., Ellinor, P. T., Ezekowitz, M. D., Field, M. E., et al. (2014) · Circulation · doi:10.1161/cir.0000000000000041 · Cited by 7,145
Self-citationCommon polygenic variation contributes to risk of schizophrenia and bipolar disorder
The International Schizophrenia Consortium (2009) · Nature · doi:10.1038/nature08185 · Cited by 4,821
Genetic studies of body mass index yield new insights for obesity biology
Study, T. L. C., Locke, A. E., The ADIPOGen Consortium, The AGEN-BMI Working Group, The CARDIOGRAMplusC4D Consortium, The CKDGen Consortium, The, G. L. G. C., The, I. C. B. P., The MAGIC Investigators, The MuTHER Consortium, et al. (2015) · Nature · doi:10.1038/nature14177 · Cited by 4,534
Self-citation
Cited by
Sorted by citations
Items 101–200 of 1,006
Weissbrod, O., Kanai, M., Shi, H., Gazal, S., Peyrot, W. J., Khera, A. V., Okada, Y., The Biobank Japan Project, Matsuda, K., Yamanashi, Y., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01036-9 · Cited by 262
Self-citationManaging Atherosclerotic Cardiovascular Risk in Young Adults
Stone, N. J., Smith, S. C., Orringer, C. E., Rigotti, N. A., Návar, A. M., Khan, S. S., Jones, D. W., Goldberg, R. B., Mora, S., Blaha, M. J., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.016 · Cited by 255
Genetics of Common, Complex Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2019) · Cell · doi:10.1016/j.cell.2019.02.015 · Cited by 246
Self-citationBenefits of the Mediterranean diet: Epidemiological and molecular aspects
Serra‐Majem, L., Román‐Viñas, B., Sánchez‐Villegas, A., Guasch‐Ferré, M., Corella, D., & Vecchia, C. L. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.06.001 · Cited by 259
Damask, A., Steg, P. G., Schwartz, G. G., Szarek, M. J., Hagström, E., Badimón, L., Chapman, M. J., Boileau, C., Tsimikas, S., Ginsberg, H. N., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.044434 · Cited by 241
Klarin, D. M., Program, V. A. M. V., Busenkell, E., Judy, R., Lynch, J. A., Levin, M. G., Haessler, J., Aragam, K. G., Chaffin, M. D., Haas, M., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0519-3 · Cited by 239
Self-citationPerucca, P., Bahlo, M., & Berkovic, S. F. (2020) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-120219-074937 · Cited by 244
Composite Pain Biomarker Signatures for Objective Assessment and Effective Treatment
Tracey, I., Woolf, C. J., & Andrews, N. A. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.019 · Cited by 246
How genome-wide association studies (GWAS) made traditional candidate gene studies obsolete
Duncan, L. E., Ostacher, M. J., & Ballon, J. S. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0389-5 · Cited by 241
Ouahed, J., Spencer, E. A., Kotlarz, D., Shouval, D. S., Kowalik, M., Peng, K., Field, M., Grushkin-Lerner, L., Pai, S., Bousvaros, A., et al. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz259 · Cited by 230
Wang, Y., Zhang, Y., Lin, Z., Zhang, H., Wang, T.-Y., Cao, Y., Morris, D. L., Sheng, Y., Yin, X., Zhong, S.-L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21049-y · Cited by 242
DNA methylation-based predictors of health: applications and statistical considerations
Yousefi, P., Suderman, M. J., Langdon, R., Whitehurst, O., Smith, G. D., & Relton, C. L. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00465-w · Cited by 233
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
Zaman, S. J., Wasfy, J. H., Kapil, V., Ziaeian, B., Parsonage, W. A., Sriswasdi, S., Chico, T., Capodanno, D., Colleran, R., Sutton, N. R., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00055-8 · Cited by 236
Zheng, Z., Liu, S., Sidorenko, J., Wang, Y., Lin, T., Yengo, L., Turley, P., Ani, A., Wang, R., Nolte, I. M., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01704-y · Cited by 251
Oligogenic inheritance of a human heart disease involving a genetic modifier
Gifford, C. A., Ranade, S. S., Samarakoon, R., Salunga, H. T., de Soysa, Y., Huang, Y., Zhou, P., Elfenbein, A., Wyman, S. K., Bui, Y. K., et al. (2019) · Science · doi:10.1126/science.aat5056 · Cited by 223
Marston, N., Kamanu, F., Nordio, F., Gurmu, Y., Roselli, C., Sever, P., Pedersen, T. R., KEECH, A. C., Wang, H., Pineda, A. L., et al. (2019) · Circulation · doi:10.1161/circulationaha.119.043805 · Cited by 219
Self-citationZheutlin, A. B., Dennis, J. K., Linnér, R. K., Moscati, A., RESTREPO, N. A., Straub, P., Ruderfer, D. M., Castro, V. M., Chen, C., Ge, T., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18091085 · Cited by 219
Lennon, N. J., Kottyan, L. C., Kachulis, C., Abul‐Husn, N. S., Arias, J. D., Belbin, G. M., Below, J. E., Berndt, S. I., Chung, W. K., Cimino, J. J., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02796-z · Cited by 221
Self-citationThe genetic basis of major depression
Kendall, K. M., Van Assche, E., Andlauer, T. F. M., Choi, K. W., Luykx, J. J., Schulte, E. C., & Lu, Y. (2021) · Psychological Medicine · doi:10.1017/s0033291721000441 · Cited by 213
Suwinski, P., Ong, C. K., Ling, M. H., Poh, Y. M., Khan, A. M., & Ong, H. S. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00049 · Cited by 218
Patel, A. P., Wang, M., Kartoun, U., Ng, K., & Khera, A. V. (2021) · Circulation · doi:10.1161/circulationaha.120.052430 · Cited by 215
Self-citationHasbani, N. R., Ligthart, S., Brown, M. R., Heath, A. S., Bebo, A., Ashley, K. E., Boerwinkle, E., Morrison, A. C., Folsom, A. R., Aguilar, D. A., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.053730 · Cited by 215
Kiryluk, K., Sánchez, E., Zhou, S., Zanoni, F., Liu, L., Mladkova, N., Khan, A., Marasà, M., Zhang, J. Y., Balderes, O., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01422-x · Cited by 212
Genetics of Atrial Fibrillation in 2020
Roselli, C., Rienstra, M., & Ellinor, P. T. (2020) · Circulation Research · doi:10.1161/circresaha.120.316575 · Cited by 218
Self-citationMonogenic and polygenic inheritance become instruments for clonal selection
Loh, P., Genovese, G., & McCarroll, S. A. (2020) · Nature · doi:10.1038/s41586-020-2430-6 · Cited by 210
Ni, G., Zeng, J., Revez, J. A., Wang, Y., Zheng, Z., Ge, T., Restuadi, R., Kiewa, J., Nyholt, D. R., Coleman, J. R. I., et al. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.04.018 · Cited by 213
Review of methods for detecting glycemic disorders
Bergman, M., Abdul‐Ghani, M. A., DeFronzo, R. A., Manco, M., Sesti, G., Fiorentino, T. V., Ceriello, A., Rhee, M. K., Phillips, L. S., Chung, S. T., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108233 · Cited by 210
Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk
Thomas, M., Sakoda, L. C., Hoffmeister, M., Rosenthal, E. A., Lee, J. K., van Duijnhoven, F. J. B., Platz, E. A., Wu, A. H., Dampier, C. H., de la Chapelle, A., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.07.006 · Cited by 203
Richardson, T. G., Harrison, S., Hemani, G., & Davey Smith, G. (2019) · eLife · doi:10.7554/elife.43657 · Cited by 198
“A recent study by Khera and colleagues (Khera et al., 2018) reported a similar odds ratio for CHD in their analysis (OR:>3.”
BackgroundInitiative, N. H. U. B., Julkunen, H., Cichońska, A., Slagboom, P. E., & Würtz, P. (2021) · eLife · doi:10.7554/elife.63033 · Cited by 200
Polygenic inheritance, GWAS, polygenic risk scores, and the search for functional variants
Crouch, D. J. M., & Bodmer, W. F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005634117 · Cited by 211
Meijers, W. C., Bayés‐Genís, A., Mebazaa, A., Bauersachs, J. K., Cleland, J. G. F., Coats, A. J. S., Januzzi, J. L., Maisel, A. S., McDonald, K., Mueller, T., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2346 · Cited by 206
Wells, P. M., Adebayo, A. S., Bowyer, R. C. E., Freidin, M. B., Finckh, A., Strowig, T., Lesker, T. R., Alpizar-Rodriguez, D., Gilbert, B., Kirkham, B., et al. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30064-3 · Cited by 192
Translational genomics and precision medicine: Moving from the lab to the clinic
Zeggini, E., Gloyn, A. L., Barton, A. C., & Wain, L. V. (2019) · Science · doi:10.1126/science.aax4588 · Cited by 194
Discovery and implications of polygenicity of common diseases
Visscher, P. M., Yengo, L., Cox, N. J., & Wray, N. R. (2021) · Science · doi:10.1126/science.abi8206 · Cited by 199
Kachuri, L., Graff, R. E., Smith-Byrne, K., Meyers, T. J., Rashkin, S. R., Ziv, E., Witte, J. S., & Johansson, M. (2020) · Nature Communications · doi:10.1038/s41467-020-19600-4 · Cited by 196
The road ahead in genetics and genomics
McGuire, A. L., Gabriel, S., Tishkoff, S. A., Wonkam, A., Chakravarti, A., Furlong, E. E. M., Treutlein, B., Meissner, A., Chang, H. Y., López-Bigas, N., et al. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-020-0272-6 · Cited by 188
African genetic diversity and adaptation inform a precision medicine agenda
Pereira, L., Mutesa, L., Tindana, P. O., & Ramsay, M. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-020-00306-8 · Cited by 194
From Detecting the Vulnerable Plaque to Managing the Vulnerable Patient
Arbab‐Zadeh, A., & Fuster, V. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.062 · Cited by 187
Abraham, G., Malik, R., Yonova‐Doing, E., Salim, A., Wang, T., Danesh, J., Butterworth, A. S., Howson, J. M. M., Inouye, M., & Dichgans, M. (2019) · Nature Communications · doi:10.1038/s41467-019-13848-1 · Cited by 191
Stroke genetics: discovery, biology, and clinical applications
Dichgans, M., Pulit, S. L., & Rosand, J. M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30043-2 · Cited by 187
Cardiovascular disease: The rise of the genetic risk score
Knowles, J. W., & Ashley, E. A. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002546 · Cited by 182
Evaluating the promise of inclusion of African ancestry populations in genomics
Bentley, A. R., Callier, S., & Rotimi, C. N. (2020) · npj Genomic Medicine · doi:10.1038/s41525-019-0111-x · Cited by 189
Amariuta, T., Ishigaki, K., Sugishita, H., Ohta, T., Koido, M., Dey, K. K., Matsuda, K., Murakami, Y., Price, A. L., Kawakami, E., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-00740-8 · Cited by 184
Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues
Lewis, A. C. F., & Green, R. C. (2021) · Genome Medicine · doi:10.1186/s13073-021-00829-7 · Cited by 188
Development of a clinical polygenic risk score assay and reporting workflow
Hao, L., Kraft, P. L., Berriz, G. F., Hynes, E. D., Koch, C., Kumar, P. K. V., Parpattedar, S. S., Steeves, M. A., Yu, W., Antwi, A. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01767-6 · Cited by 181
Self-citationForrest, I. S., Petrazzini, B. O., Duffy, Á., Park, J. K., Márquez‐Luna, C., Jordan, D. M., Rocheleau, G., Cho, J. H., Rosenson, R. S., Narula, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)02079-7 · Cited by 182
Sevakula, R. K., Au-Yeung, W.-T. M., Singh, J. P., Heist, E. K., Isselbacher, E. M., & Armoundas, A. A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013924 · Cited by 182
Luo, Y., Kanai, M., Choi, W., Li, X., Sakaue, S., Yamamoto, K., Ogawa, K., Gutiérrez‐Arcelus, M., Gregersen, P. K., Stuart, P. E., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00935-7 · Cited by 177
Self-citationMalaria Genomic Epidemiology Network, Band, G., Le, S. Q., Clarke, G. M., Kivinen, K., Hubbart, C., Jeffreys, A. E., Rowlands, K., Leffler, E. M., Jallow, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13480-z · Cited by 182
Improved genetic prediction of complex traits from individual-level data or summary statistics
Zhang, Q., Privé, F., Vilhjálmsson, B. J., & Speed, D. (2021) · Nature Communications · doi:10.1038/s41467-021-24485-y · Cited by 179
Polygenic scores in biomedical research
Kullo, I. J., Lewis, C. M., Inouye, M., Martin, A. R., Ripatti, S., & Chatterjee, N. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00470-z · Cited by 185
Cardiovascular calcification: artificial intelligence and big data accelerate mechanistic discovery
Rogers, M. A., & Aïkawa, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0123-8 · Cited by 173
Davis, C. M., Apter, A. J., Casillas, A. M., Foggs, M. B., Louisias, M., Morris, E. C., Nanda, A., Nelson, M. R., Ogbogu, P. U., Walker-McGill, C. L., et al. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.02.034 · Cited by 173
Habuza, T., Navaz, A. N., Hashim, F., Alnajjar, F., Zaki, N., Serhani, M. A., & Statsenko, Y. A. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100596 · Cited by 179
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. M., Викторович, А. М., Alexandrova, L. M., Анциферова, А. А., Dm, A., Ахмеджанов, Н. М., Balanova, Y. А., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3235 · Cited by 197
Resource profile and user guide of the Polygenic Index Repository
Becker, J., Burik, C. A. P., Goldman, G., Wang, N., Jayashankar, H., Bennett, M., Belsky, D. W., Linnér, R. K., Ahlskog, R., Kleinman, A., et al. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01119-3 · Cited by 179
Ge, T., Irvin, M. R., Patki, A., Srinivasasainagendra, V., Lin, K., Tiwari, H. K., Armstrong, N. D., Benoit, B., Chen, C., Choi, K. W., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01074-2 · Cited by 178
Systematic comparison of family history and polygenic risk across 24 common diseases
Mars, N., Lindbohm, J. V., Parolo, P. D. B., Widén, E., Kaprio, J. A., Palotie, A. V., FinnGen, & Ripatti, S. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.10.009 · Cited by 176
Challenges and Opportunities for Developing More Generalizable Polygenic Risk Scores
Wang, Y., Tsuo, K., Kanai, M., Neale, B. M., & Martin, A. R. (2022) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-111721-074830 · Cited by 173
Unique roles of rare variants in the genetics of complex diseases in humans
Momozawa, Y., & Mizukami, K. (2021) · Journal of Human Genetics · doi:10.1038/s10038-020-00845-2 · Cited by 161
Genome-wide polygenic score to predict chronic kidney disease across ancestries
Khan, A., Turchin, M. C., Patki, A., Srinivasasainagendra, V., Shang, N., Nadukuru, R., Jones, A. C., Małolepsza, E., Dikilitas, O., Kullo, I. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01869-1 · Cited by 168
Aubourg, G., Rice, S. J., Bruce-Wootton, P., & Loughlin, J. A. (2021) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2021.03.002 · Cited by 178
Lu, X., Liu, Z., Cui, Q., Liu, F., Li, J., Niu, X., Shen, C., Hu, D., Huang, K., Chen, J., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac093 · Cited by 165
The role of polygenic risk and susceptibility genes in breast cancer over the course of life
Mars, N., Widén, E., Kerminen, S., Meretoja, T. J., Pirinen, M., Parolo, P. D. B., Palta, P., FinnGen, Havulinna, A. S., Elliott, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19966-5 · Cited by 167
Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses
Sun, L., Pennells, L. A. M., Kaptoge, S. K., Nelson, C. P., Abraham, G., Arnold, M., Bell, S., Bolton, T., Burgess, S., Dudbridge, F., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003498 · Cited by 172
Uncovering the Genetic Architecture of Major Depression
McIntosh, A. M., Sullivan, P. F., & Lewis, C. M. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.022 · Cited by 165
Polygenic architecture of rare coding variation across 394,783 exomes
Weiner, D. J., Nadig, A., Jagadeesh, K. A., Dey, K. K., Neale, B. M., Robinson, E., Karczewski, K. J., & O’Connor, L. J. (2023) · Nature · doi:10.1038/s41586-022-05684-z · Cited by 168
Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction
Riveros-Mckay, F., Weale, M. E., Moore, R., Selzam, S., Krapohl, E. M. L., Sivley, R. M., Tarran, W. A., Sørensen, P. B., Lachapelle, A. S., Griffiths, J. A., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003304 · Cited by 163
Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review
Kenner, B., Chari, S. T., Kelsen, D., Klimstra, D. S., Pandol, S. J., Rosenthal, M., Rustgi, A. K., Taylor, J. A., Yala, A., Abul-Husn, N., et al. (2021) · Pancreas · doi:10.1097/mpa.0000000000001762 · Cited by 158
Jurgens, S. J., Choi, S. H., Morrill, V. N., Chaffin, M. D., Pirruccello, J. P., Halford, J. L., Weng, L.-C. C., Nauffal, V., Roselli, C., Hall, A. W., et al. (2022) · Nature Genetics · doi:10.1038/s41588-021-01011-w · Cited by 166
Self-citationAnnual Research Review: Perspectives on progress in ADHD science – from characterization to cause
Sonuga‐Barke, E. J. S., Becker, S. P., Bölte, S., Castellanos, F. X., Franke, B., Newcorn, J. H., Nigg, J. T., Rohde, L. A., & Simonoff, E. (2023) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13696 · Cited by 157
Precision medicine and therapies of the future
Sisodiya, S. (2020) · Epilepsia · doi:10.1111/epi.16539 · Cited by 139
Bonnefond, A., Ranjit Unnikrishnan, I., Doria, A., Vaxillaire, M., Kulkarni, R., Mohan, V., Trischitta, V., & Froguel, P. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00421-w · Cited by 167
Opportunistic genomic screening. Recommendations of the European Society of Human Genetics
On behalf of the European Society of Human Genetics, de Wert, G. M. W. R., Dondorp, W., Clarke, A. J., Dequeker, E. M. C., Cordier, C., Deans, Z. C., van El, C. G., Fellmann, F., Hastings, R. J., et al. (2020) · European Journal of Human Genetics · doi:10.1038/s41431-020-00758-w · Cited by 164
The illusion of polygenic disease risk prediction
Wald, N., & Old, R. W. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0418-5 · Cited by 154
Primary prevention of ischaemic heart disease: populations, individuals, and health professionals
Gupta, R., & Wood, D. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31893-8 · Cited by 159
Proteomics and lipidomics in atherosclerotic cardiovascular disease risk prediction
Nurmohamed, N. S., Kraaijenhof, J. M., Mayr, M., Nicholls, S. J., Köenig, W., Catapano, A. L., & Stroes, E. S. G. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad161 · Cited by 156
Ghouse, J., Tragante, V., Ahlberg, G., Rand, S. A., Jespersen, J. B., Leinoe, E. B., Vissing, C. R., Trudsø, L. C., Jónsdóttir, I., Banasik, K., et al. (2023) · Nature Genetics · doi:10.1038/s41588-022-01286-7 · Cited by 156
Clinical utility of polygenic risk scores for coronary artery disease
Klarin, D., & Natarajan, P. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00638-w · Cited by 152
Self-citationYanes, T., Young, M., Meiser, B., & James, P. A. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01260-3 · Cited by 152
Igo, R. P., Kinzy, T. G., & Bailey, J. N. C. (2019) · Current Protocols in Human Genetics · doi:10.1002/cphg.95 · Cited by 160
Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association
Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.011 · Cited by 148
Polygenic burden in focal and generalized epilepsies
Leu, C., Stevelink, R., Smith, A. C. W., Goleva, S. B., Kanai, M., Ferguson, L., Campbell, C., Kamatani, Y., Okada, Y., Sisodiya, S. M., et al. (2019) · Brain · doi:10.1093/brain/awz292 · Cited by 152
History of Nonalcoholic Fatty Liver Disease
Lonardo, A., Leoni, S., Alswat, K., & Fouad, Y. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165888 · Cited by 154
Márquez‐Luna, C., Gazal, S., Loh, P., Kim, S. S., Furlotte, N. A., Auton, A., Agee, M., Alipanahi, B., Bell, R. K., Bryc, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25171-9 · Cited by 151
Significant sparse polygenic risk scores across 813 traits in UK Biobank
Tanigawa, Y., Qian, J., Venkataraman, G. R., Justesen, J. M., Li, R., Tibshirani, R. J., Hastie, T. J., & Rivas, M. A. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010105 · Cited by 153
The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk
Nayor, M. G., Brown, K., & Vasan, R. S. (2021) · Circulation Research · doi:10.1161/circresaha.120.315890 · Cited by 149
Polygenic Scores to Assess Atherosclerotic Cardiovascular Disease Risk
Aragam, K. G., & Natarajan, P. (2020) · Circulation Research · doi:10.1161/circresaha.120.315928 · Cited by 148
Self-citationDikilitas, O., Schaid, D. J., Kosel, M., Carroll, R. J., Chute, C. G., Denny, J. C., Fedotov, A., Feng, Q., Hakonarson, H. H., Jarvik, G. P., et al. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.04.002 · Cited by 148
Marshall, C. R., Chowdhury, S., Taft, R. J., Lebo, M. S., Buchan, J. G., Harrison, S. M., Rowsey, R. A., Klee, E. W., Liu, P., Worthey, E. A., et al. (2020) · npj Genomic Medicine · doi:10.1038/s41525-020-00154-9 · Cited by 145
Genetics and epigenetics of IBD
Annese, V. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104892 · Cited by 149
A systematic review and quality assessment of individualised breast cancer risk prediction models
Louro, J., Posso, M., Boon, M. H., Román, M., Domingo, L., Castells, X., & Sala, M. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0476-8 · Cited by 140
Beyond the One Gene–One Disease Paradigm
Cerrone, M., Remme, C. A., Tadros, R., Bezzina, C. R., & Delmar, M. (2019) · Circulation · doi:10.1161/circulationaha.118.035954 · Cited by 145
Lahrouchi, N., Tadros, R., Crotti, L., Mizusawa, Y., Postema, P. G., Beekman, L., Walsh, R., Hasegawa, K., Barc, J., Ernsting, M., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045956 · Cited by 141
Self-citationFamilial hypercholesterolaemia: evolving knowledge for designing adaptive models of care
Watts, G. F., Gidding, S. S., Mata, P., Pang, J., SULLIVAN, D. R., Yamashita, S., Raal, F. J., Santos, R. D., & Ray, K. K. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0325-8 · Cited by 144
Molecular Mechanisms of Vascular Health: Insights From Vascular Aging and Calcification
Sutton, N. R., Malhotra, R. K., Hilaire, C. S., Aïkawa, E., Blumenthal, R. S., Gackenbach, G., Goyal, P., Johnson, A. L., Nigwekar, S. U., Shanahan, C. M., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317332 · Cited by 140
Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases
Bick, D. P., Jones, M. C., Taylor, S. L., Taft, R. J., & Belmont, J. W. (2019) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106111 · Cited by 145
Epilepsy genetics: clinical impacts and biological insights
Ellis, C. A., Petrovski, S., & Berkovic, S. F. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30269-8 · Cited by 140
Accurate and Scalable Construction of Polygenic Scores in Large Biobank Data Sets
Yang, S., & Zhou, X. (2020) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2020.03.013 · Cited by 138
Metadata
- Authors
- Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., & Kathiresan, S.
- Affiliations
- Broad Institute (US)
- Corresponding author
- Kathiresan, Sekar
- ORCID
- Venue
- Nature Genetics
- Published
- 2018-08-13
- Volume
- 50
- Issue
- 9
- Pages
- 1219-1224
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- PMC
- PMC6128408
- OpenAlex
- W2886752110
- Semantic Scholar
- d5eb49c11d070114e2ff46224099895c6b4b1558
- Cited by
- 2,953
- References
- 46
- Citations by year
- 2026: 276 · 2025: 290 · 2024: 363 · 2023: 362 · 2022: 433 · 2021: 411 · 2020: 451 · 2019: 307 · 2018: 57
- FWCI
- 189.86
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, other-oa)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- PMC
- Funders
- Doris Duke Charitable Foundation (2014105)
- Massachusetts General Hospital (HL007208)
- Harvard Catalyst (TR001100)
- Vertex Pharmaceuticals
- KR Foundation
- National Institutes of Health (KL2TR001100, HL0-07734, HL007208, T32-HL007734)
- National Heart, Lung, and Blood Institute (R01HL127564, HL007208, HL127564, R01HL128914, T-32HL007734, K08HL140203, HL007734, K23HL114724, K24HL105780, R01HL142711, R01HL092577, T32HL007208, R01HL139731)
- National Human Genome Research Institute (UM1HG008895)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and phenotypic traits in livestock
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
- Keywords
- polygenic risk score, monogenic mutations, common diseases, coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, breast cancer, high-risk individuals, clinical risk stratification
- MeSH terms
- Adult, Aged, Disease, Female, Humans, Male, Middle Aged, Mutation, Risk Factors, Genetic Predisposition to Disease, Multifactorial Inheritance, Polymorphism, Single Nucleotide, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
